Bioservo Technologies

Germany is Europe's largest market in terms of population and over 8.7 million people have disabilities of the types Carbonhand is designed for. External analyses show that, conservatively, over 1 million of these people could be helped by Carbonhand to cope better with everyday life, become more independent, and have a better quality of life.

So far this year, Bioservo has received orders from Germany for 21 Carbonhand systems with an order value of just over SEK 1.4 million. Of these, 16 have been ordered for patients suffering from stroke, MS and other neurological diseases. In addition, 5 Carbonhand systems have been delivered to distributors for use in patient trials and to introduce Carbonhand within the healthcare system.

"We are very pleased with the development we see in Germany. The sales increase of 300% is due to several factors, partly because our new version of Carbonhand can help significantly more patients, but above all, the awareness and acceptance of Carbonhand has contributed to making it easier to get Carbonhand prescribed. We hope and believe that what we are now witnessing is the beginning of a breakthrough in the German market and that we can help even more people to increased independence.", says Petter Bäckgren, CEO of Bioservo.

For more information, please contact,
Petter Bäckgren, CEO, Bioservo Technologies AB
Phone: +468 21 17 10
petter.backgren@bioservo.com

Mikael Wester, Marketing Director, Bioservo Technologies AB
Phone: +468 21 17 10
mikael.wester@bioservo.com

About Bioservo Technologies
Bioservo Technologies AB (publ) is a world-leading company in wearable muscle-strengthening systems for people in need of extra strength and endurance. All our innovative products and systems are designed to keep people strong, healthy, and efficient. The company has a unique global position within soft exoskeleton technology for the hand, both for industrial applications to improve the health of workers and to improve the quality of life for people with reduced muscle strength. Bioservo Technologies was founded in 2006 in collaboration between researchers at the Royal Institute of Technology and a doctor at Karolinska University Hospital. Bioservo Technologies is a Swedish public limited company with headquarters in Stockholm.

FNCA Sweden AB is the company’s Certified Adviser on Nasdaq First North.
For more information, please visit www.bioservo.com